



**THE CHARACTERIZATION OF SPONTANEOUS AND
VACCINE-DRIVEN ANTIGEN-SPECIFIC CYTOTOXIC T
LYMPHOCYTE RESPONSES IN MELANOMA PATIENTS**

CAROLINE L. SMITH

THE DEPARTMENT OF MEDICINE, THE UNIVERSITY OF ADELAIDE

OCTOBER 2004

TABLE OF CONTENTS

<u>THESIS ABSTRACT</u>	6
<u>STATEMENT OF ORIGINALITY</u>	7
<u>PUBLICATIONS RELEVANT TO THIS THESIS</u>	8
<u>PRESENTATIONS RELEVANT TO THIS THESIS</u>	9
<u>ACKNOWLEDGEMENTS</u>	10
<u>ABBREVIATIONS</u>	13
<u>Chapter 1 General Introduction</u>	16
<i>1.1 Preface</i>	17
<i>1.2 The Immune System</i>	18
1.2.1 Innate Immunity	18
1.2.2 Adaptive Immunity.....	21
1.2.2.1 Antigen Specificity	21
1.2.2.2 Dendritic Cells: a link between Innate and Adaptive Immunity	22
1.2.2.3 T cell Priming	23
1.2.2.4 T cell Expansion and Differentiation	24
1.2.2.5 CD8 ⁺ T cell Effector Function	25
1.2.2.6 T cell Memory	25
1.2.2.7 Signal 1, The MHC Class I/peptide complex: What do CD8 ⁺ T cells recognize?	26
1.2.2.8 Cross-Priming.....	29
1.2.2.9 T cell Self-Tolerance	29
1.2.2.10 Analysis of Antigen-Specific Cellular Immune Responses	31
<i>1.3 Tumour Immunology</i>	34
1.3.1 Historical Perspective	34
1.3.2 Immunosurveillance	35
1.3.3 Evidence of Anti-tumour Immune Responses	37
1.3.4 Tumour Antigen Discovery	39
1.3.5 Tumour Antigen Classification	42
1.3.5.1 Cancer-testis Antigens	42
1.3.5.2 Differentiation Antigens	43
1.3.5.3 Tumour-specific Antigens	43
1.3.5.4 Widely Expressed Antigens.....	43
1.3.5.5 Viral Antigens.....	44
1.3.6 Tumour Immunotherapy.....	44
1.3.6.1 The Aims of Immunotherapy.....	44
1.3.6.2 Historical Perspective	45
1.3.6.3 Immunotherapeutic Strategies	46
1.3.6.4 The Hurdle of Tumour Escape.....	47
<i>1.4 Malignant Melanoma</i>	49
1.4.1 Melanocytes.....	49

1.4.2 Aetiology	49
1.4.3 Incidence	50
1.4.4 Histological Classification and Staging.....	51
1.4.5 Treatment.....	51
<i>1.5 Thesis Aims</i>	53
Chapter 2 Materials and Methods.....	54
<i>2.1 Clinical Sample Processing and Cell Line Culture</i>	55
2.1.1 Peripheral Blood Monocyte Separation and Cryopreservation.....	55
2.1.2 Tumour Infiltrated Lymph Node (TILN) processing.....	55
2.1.3 Cell Line Culture	55
<i>2.2 Generation of epitope-specific CTL clones and polyclonal cell lines</i>	56
<i>2.3 Analysis of Cellular Immune Responses</i>	57
2.3.1 Reagents	57
2.3.1.1 Peptides.....	57
2.3.1.2 Tetramers	57
2.3.1.2.1 Production of Recombinant Proteins	57
2.3.1.2.2 Denaturing SDS-PAGE Analysis of Proteins	58
2.3.1.2.3 Tetramer synthesis	60
2.3.1.2.4 Tetramer Dose Titration.....	65
2.3.1.3 Viral Expansion for use in immunoassays.....	67
2.3.2 Immunoassays	67
2.3.2.1 Tetramer and phenotypic analysis of CTL by Flow Cytometry.....	67
2.3.2.2 Recall Assay	69
2.3.2.3 ELISPOT Assay.....	69
2.3.2.3.1 Epitope-specific CTL responses	69
2.3.2.3.2 Cellular Responses to whole Modified Vaccinia Ankara (MVA) virus.....	71
<i>2.4 Analysis of Antibody Responses</i>	71
2.4.1 Anti-MVA IgG ELISA.....	71
<i>2.5 Analysis of melan-A Tumour Antigen Expression</i>	72
<i>2.6 Clinical Trial Protocol</i>	74
2.6.1 Study Design	74
2.6.2 Investigational Agents.....	75
2.6.2.1 The Mel3 polyepitope string.....	75
2.6.2.2 DNA.Mel3	77
2.6.2.3 MVA.Mel3	77
2.6.3 Treatment Arms and Randomization.....	78
2.6.4 Study Sites.....	80
2.6.5 Regulatory Submissions and Sponsorship.....	80
2.6.5 Patients	80
2.6.5.1 Inclusion criteria	80
2.6.5.2 Exclusion criteria.....	81
2.6.6 Safety Assessments	82
2.6.7 Immunomonitoring Schedule.....	83
Chapter 3 Phenotypic and functional analyses of melan-A₂₆₋₃₅-specific CTL in melanoma patients and normal healthy blood donors: A shift in the phenotype of melan-A₂₆₋₃₅-specific CTL identifies patients with an active tumour-specific immune response	84
3.1 Abstract.....	85
3.2 Introduction.....	86

<u>3.3 Experimental Procedures</u>	91
3.3.1 Subjects	91
3.3.2 Immunoassays	91
<u>3.4 Results</u>	93
3.4.1 Normal Healthy Donors: Melan-A ₂₆₋₃₅ -specific CD8 ⁺ T lymphocytes have a naïve phenotype	93
3.4.2 Melanoma Patients: Melan-A ₂₆₋₃₅ -specific CD8 ⁺ T lymphocytes have two distinct phenotypes	93
3.4.3 Normal Healthy Donors: Melan-A ₂₆₋₃₅ -specific CD8 ⁺ T lymphocytes are functionally naïve	98
3.4.4 Melanoma Patient PBL: Melan-A ₂₆₋₃₅ -specific CD8 ⁺ T lymphocyte effector function correlates with phenotype	98
3.4.5 Melanoma-infiltrated lymph nodes: phenotype and function of melan-A ₂₆₋₃₅ -specific CD8 ⁺ T lymphocytes	103
<u>3.5 Discussion</u>	108
3.5.1 Quantification of melan-A ₂₆₋₃₆ -specific CD8 ⁺ T lymphocytes in peripheral blood	108
3.5.2 Phenotype of melan-A ₂₆₋₃₅ -specific CTL in peripheral blood and TiLN.....	108
3.5.3 Priming of melan-A ₂₆₋₃₅ -specific CTL is often weak in melanoma patients.....	110
3.5.4 Clinical Relevance of Active Immunity against melan-A: “too little, too late.”	112
3.5.5 The paradox of melan-A ₂₆₋₃₅ -specific CD8 ⁺ T lymphocytes in normal healthy individuals.....	113
3.5.6 Implications for Melan-A as an Immunotherapeutic Target.....	115

Chapter 4 CTL responses specific for melanoma tumour antigen epitopes in patients participating in a phase I clinical trial of recombinant plasmid DNA and Modified Vaccinia Ankara 117

<u>4.1 Abstract</u>	118
<u>4.2 Introduction</u>	119
<u>4.3 Methodology and Experimental Procedures</u>	124
<u>4.4 Results</u>	126
4.4.1 Patients	126
4.4.2 Safety.....	128
4.4.3 Expansion of melan-A ₂₆₋₃₅ -specific CTL.....	130
4.4.4 Vaccine-driven melan-A ₂₆₋₃₅ -specific CTL have an effector phenotype	133
4.4.5 Vaccine-driven melan-A ₂₆₋₃₅ -specific CTL have effector function	137
4.4.6 Lack of direct evidence of DNA priming.....	141
4.4.7 Lack of CTL responses to other Mel3 recombinant epitopes.....	142
4.4.8 Pre-existing NY-ESO-1 ₁₅₇₋₁₆₅ -specific CTL response in patient 12	142
4.4.9 Anti-poxviral antibody responses.....	148
<u>4.5 Discussion</u>	150

Chapter 5 Characterization of poxviral-specific cellular immune responses and the identification of a new vaccinia virus HLA-A*0201-restricted CTL epitope 155

<u>5.1 Abstract</u>	156
<u>5.2 Introduction</u>	157
<u>5.3 Methodology and Experimental Procedures</u>	162
5.3.1 Selection of candidate peptides for analysis.....	163
<u>5.4 Results</u>	166
5.4.1 Cellular response to whole MVA virus	166
5.4.2 Epitope prediction for proteins p4a and D8L	170
5.4.3 Ex vivo ELISPOT analysis of p4a- and D8L-encoded peptides.....	172
5.4.4 Ex vivo tetramer analysis for p4a- and D8L-encoded candidate epitopes.....	175
5.4.5 Ex vivo ELISPOT analysis of peptides screened in murine models.....	175
5.4.6 Tetramer analysis of the ILD candidate epitope.....	178

5.5 Discussion.....	180
Chapter 6 Characterization of vaccinia virus epitope-specific CTL responses in patients receiving repeated injections of a recombinant MVA vaccine	188
6.1 Abstract.....	189
6.2 Introduction.....	190
6.3 Experimental Procedures.....	192
6.4 Results.....	193
6.4.1 Kinetics of CTL responses specific for HLA-A*0201-restricted vaccinia-encoded epitopes.....	193
6.4.2 Phenotypic analyses of vaccinia-specific CTL responses.....	197
6.4.3 Effector function of KVD- and ILD-specific CTL.....	201
6.4.4 Generation of a KVD-specific polyclonal CTL line.....	205
6.4.5 A comparison of CTL responses specific for recombinant and vaccinia-encoded CTL.....	207
6.5 Discussion.....	210
Chapter 7 General Discussion.....	216
7.1 Dose of Immunotherapeutic Agents	217
7.2 Choice of Cancer Vaccine Immunogen: A Future for Plasmid DNA and Poxviruses?.....	218
7.3 Choice of Foreign Construct.....	219
7.4 The Clinical Application of Analogue Peptides.....	220
7.5 Immunogenicity as a Clinical Trial End Point.....	221
7.6 Patient Population.....	224
7.7 Study Design.....	225
8 Bibliography.....	228

THESIS ABSTRACT

The Characterization of Spontaneous and Vaccine-Driven Cytotoxic T Lymphocyte Responses in Melanoma Patients

Caroline L. Smith

**The Department of Medicine, The University of Adelaide
Thesis submitted for the Degree of Doctor of Philosophy**

The last decade has witnessed a huge expansion in the field of Tumour Immunology. A large number of tumour antigens recognized by T lymphocytes have been identified and new techniques have enabled the direct *ex vivo* analysis of epitope-specific cytotoxic T lymphocytes (CTL). These developments provide the tools with which spontaneous tumour antigen-specific CTL responses can be characterized in detail, have facilitated the development of antigen-specific tumour immunotherapeutic strategies, and have heralded a new era of immunomonitoring in clinical trials. In this work, *ex vivo* phenotypic and functional analyses of CTL specific for an HLA-A*0201-restricted epitope encoded by the melan-A tumour differentiation antigen (melan-A₂₆₋₃₅) were performed on samples from melanoma patients and normal healthy donors. *Ex vivo* tetramer analysis revealed circulating melan-A₂₆₋₃₅-specific T lymphocytes in 50% of both patients and normal donors. Phenotypic analysis of tetramer⁺ cells was correlated with *ex vivo* assays of CTL function. In the normal donors and approximately 50% of patients, the melan-A₂₆₋₃₅-specific cells were always phenotypically and functionally naïve. However, in the remaining patients, a proportion of melan-A₂₆₋₃₅-specific cells were phenotypically antigen-experienced, and functional responses to peptide could readily be detected *ex vivo*. The observation in patients, that tumour antigen-specific CTL responses with effector function are “too little, too late”, provided the basis for a clinical trial of recombinant plasmid DNA and Modified Vaccinia Ankara in patients with surgically-treated melanoma and a high risk of disease recurrence. Both vaccines were engineered to encode the same polyepitope string of seven HLA-A2- and HLA-A1-restricted tumour antigen epitopes, including the high affinity melan-A₂₆₋₃₅ analogue. Immunomonitoring, which included detailed kinetic analyses of tetramer⁺ cells, demonstrated that MVA was capable of generating an expansion of melan-A₂₆₋₃₅-specific CTL with effector function in approximately 50% of patients. However, no responses to the other tumour antigen epitopes were seen. A detailed analysis of CTL responses specific for recently-identified vaccinia-encoded epitopes (including a new epitope identified as part of this work) demonstrated that CTL responses specific for the viral vector were dominant over those for the recombinant epitopes. This finding has important implications for the future design of recombinant viral vaccines.